Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.67 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23302538 | 0.93 | EGFR (0.72) | EGFRBTKALKMETINSR | |
| SCHEMBL24581823 | 0.93 | EGFR (0.68) | EGFRBTKALKMETROS1 | |
| SCHEMBL23303154 | 0.89 | EGFR (0.84) | EGFRBTKALKROS1 | |
| SCHEMBL24581821 | 0.86 | EGFR (0.73) | EGFRBTKALKMETINSR | |
| SCHEMBL23302527 | 0.85 | EGFR (0.80) | EGFRBTKALKMETINSR | |
| SCHEMBL23302834 | 0.82 | EGFR (0.63) | EGFRBTKALKMETINSR | |
| SCHEMBL23302517 | 0.81 | EGFR (0.87) | EGFRBTKALKROS1 | |
| SCHEMBL23304000 | 0.81 | EGFR (0.66) | EGFRBTKALKMETINSR | |
| SCHEMBL29758553 | 0.81 | EGFR (0.66) | EGFRBTKALKMETINSR | |
| SCHEMBL23304015 | 0.80 | EGFR (1.00) | EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421221-B2 | Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2025-09-23 | — | — | US | claimed |
| EP-4053121-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2022-09-07 | — | — | EP | claimed |
| US-20220204492-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2022-06-30 | — | — | US | claimed |
| CN-113840823-A | Novel heterocycle-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2021-12-24 | — | — | CN | claimed |
| WO-2021085888-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 온코빅스 | 2021-05-06 | — | — | WO | claimed |
| US-12421221-B2 | Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| EP-4053121-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2022-09-07 | — | — | EP | disclosed |
| US-20220204492-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2022-06-30 | — | — | US | disclosed |
| CN-113840823-A | Novel heterocycle-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2021-12-24 | — | — | CN | disclosed |
| WO-2021085888-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 온코빅스 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204492-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EGFR, ALK, FGFR1 | EGFR 1/4885BTK 226/4885ALK 2/4885 |
| US-12421221-B2 | Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | ALK, EGFR, FGFR1 | EGFR 2/4885BTK 229/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.